{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:02:39Z","timestamp":1792807359235,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Oxford NIHR Biomedical Research Centre, UK"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bpobgyn.2017.09.008","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T10:02:33Z","timestamp":1506679353000},"page":"59-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"special_numbering":"C","title":["Therapeutic HPV vaccines"],"prefix":"10.1016","volume":"47","author":[{"given":"Gemma","family":"Hancock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Dorrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpobgyn.2017.09.008_bib1","first-page":"1","article-title":"Human papillomaviruses and their possible role in squamous cell carcinomas","volume":"78","author":"zur Hausen","year":"1977","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib2","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/ijc.27485","article-title":"Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer","volume":"131","author":"Guan","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib3","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jadohealth.2010.01.016","article-title":"Beyond cervical cancer: burden of other HPV-related cancers among men and women","volume":"46","author":"Chaturvedi","year":"2010","journal-title":"J\u00a0Adolesc Health"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib4","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(14)70481-4","article-title":"Present status of human papillomavirus vaccine development and implementation","volume":"16","author":"Herrero","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Mu\u00f1oz","year":"2010","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib7","series-title":"WHO | Strategic Advisory Group of Experts (SAGE) on Immunization","year":"2017"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib8","first-page":"561","volume":"vol. 91","year":"2016"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","article-title":"Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis","volume":"88","author":"Clifford","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib10","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib11","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1086\/597309","article-title":"The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16\u201326 years","volume":"199","author":"Wheeler","year":"2009","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib12","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 virus like particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib13","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A\u00a0review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib14","series-title":"Estimated cancer incidence, mortality and prevalence worldwide in 2012 v1.0 [Internet]","author":"GLOBOCAN","year":"2012"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib15","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/AOG.0b013e318237caf4","article-title":"The clinical meaning of a cervical intraepithelial neoplasia grade 1 biopsy","volume":"118","author":"Castle","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib16","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.25635","article-title":"Expectant management versus immediate treatment for low-grade cervical intraepithelial neoplasia","volume":"117","author":"Elit","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib17","first-page":"5","article-title":"NHS cervical screening programme colposcopy and programme management public health England leads the NHS screening programmes","volume":"3","author":"Health England P","year":"2016","journal-title":"Public Heal Engl"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib18","series-title":"Cochrane database syst rev","article-title":"Surgery for cervical intraepithelial neoplasia","author":"Martin-Hirsch","year":"1999"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib19","doi-asserted-by":"crossref","first-page":"i3633","DOI":"10.1136\/bmj.i3633","article-title":"Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis","author":"Kyrgiou","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g6192","article-title":"Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis","volume":"349","author":"Kyrgiou","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1471-0528.2010.02501.x","article-title":"The volume perspective: a comparison of two excisional treatments for cervical intraepithelial neoplasia (laser versus LLETZ)","volume":"117","author":"Phadnis","year":"2010","journal-title":"BJOG"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib22","first-page":"12","article-title":"Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland","author":"Ginindza","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib23","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1158\/1078-0432.CCR-04-2599","article-title":"Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype","volume":"11","author":"Trimble","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/CEJ.0b013e3282f75ea1","article-title":"HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy","volume":"17","author":"De Vuyst","year":"2008","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.critrevonc.2012.02.008","article-title":"HPV-related (pre)malignancies of the female anogenital tract in renal transplant recipients","volume":"84","author":"Hinten","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib26","doi-asserted-by":"crossref","first-page":"7107","DOI":"10.4049\/jimmunol.1002756","article-title":"Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium","volume":"185","author":"Trimble","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib27","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1099\/vir.0.82678-0","article-title":"Resolution of cervical dysplasia is associated with T-cell proliferative responses to human papillomavirus type 16 E2","volume":"88","author":"Dillon","year":"2007","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ijc.24804","article-title":"A\u00a0prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses","volume":"126","author":"Woo","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00262-011-1092-5","article-title":"CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend","volume":"61","author":"Kim","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/sj.bjc.6602679","article-title":"T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia","volume":"93","author":"Steele","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2005.11.039","article-title":"Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix","volume":"102","author":"Monnier-Benoit","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib32","doi-asserted-by":"crossref","first-page":"7681","DOI":"10.4049\/jimmunol.180.11.7681","article-title":"Local accumulation of FOXP3+ regulatory T cells: evidence for an immune evasion mechanism in patients with large condylomata acuminata","volume":"180","author":"Cao","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib33","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/ijc.22894","article-title":"CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia","volume":"121","author":"Molling","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1089\/vim.2013.0097","article-title":"The relation of plasmacytoid dendritic cells (pDCs) and regulatory T-cells (Tregs) with HPV persistence in HIV-infected and HIV-uninfected women","volume":"27","author":"Strickler","year":"2014","journal-title":"Viral Immunol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib35","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/aji.12030","article-title":"The prevalence of cervical regulatory T cells in HPV-related cervical intraepithelial neoplasia (CIN) correlates inversely with spontaneous regression of CIN","volume":"69","author":"Kojima","year":"2013","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib36","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1046\/j.1365-2230.2002.01151.x","article-title":"Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential","volume":"27","author":"Stanley","year":"2002","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1006\/viro.2000.0789","article-title":"Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes","volume":"283","author":"Nicholls","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-065X.2011.01051.x","article-title":"Cytoplasmic DNA innate immune pathways","volume":"243","author":"Barber","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib39","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/toxsci\/kfj169","article-title":"Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts","volume":"91","author":"Sheets","year":"2006","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib40","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000053993","article-title":"Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice","volume":"43","author":"Ledwith","year":"2000","journal-title":"Intervirology"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib41","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.4049\/jimmunol.165.5.2850","article-title":"Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice","volume":"165","author":"Dupuis","year":"2000","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib42","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0264-410X(00)00246-2","article-title":"Influence of codon usage on the immunogenicity of a DNA vaccine against tetanus","volume":"19","author":"Stratford","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib43","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.imlet.2007.09.008","article-title":"DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity","volume":"114","author":"Lin","year":"2007","journal-title":"Immunol Lett"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib44","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1128\/JVI.02564-07","article-title":"Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in\u00a0vivo electroporation","volume":"82","author":"Liu","year":"2008","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib45","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.gt.3303060","article-title":"Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition","volume":"15","author":"de Mare","year":"2008","journal-title":"Gene Ther"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib46","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime\u2013boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib47","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib48","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1126\/science.1093616","article-title":"Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA","volume":"303","author":"Diebold","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2012.12.029","article-title":"Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format","volume":"166","author":"Phua","year":"2013","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","article-title":"Viral vectors as vaccine platforms: from immunogenicity to impact","volume":"41","author":"Ewer","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib51","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ijc.30679","article-title":"Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease","volume":"141","author":"Khan","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib52","doi-asserted-by":"crossref","unstructured":"Ragonnaud E, Andersson A-MC, Mariya S, et\u00a0al. Therapeutic vaccine against primate papillomavirus infections of the cervix. J Immunother. 40:51\u201361.","DOI":"10.1097\/CJI.0000000000000153"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib53","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.4049\/jimmunol.180.5.3339","article-title":"MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines","volume":"180","author":"Holst","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib54","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/sji.12522","article-title":"Breadth of T cell responses after immunization with adenovirus vectors encoding ancestral antigens or polyvalent papillomavirus antigens","volume":"85","author":"Ragonnaud","year":"2017","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib55","doi-asserted-by":"crossref","first-page":"11341","DOI":"10.1073\/pnas.93.21.11341","article-title":"Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety","volume":"93","author":"Moss","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib56","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.virol.2005.09.037","article-title":"Poxvirus entry and membrane fusion","volume":"344","author":"Moss","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib57","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/10430340460745757","article-title":"Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus","volume":"15","author":"Corona Gutierrez","year":"2004","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib58","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.cgt.7700937","article-title":"Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine","volume":"13","author":"Garc\u00eda-Hern\u00e1ndez","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00063030-200721010-00006","article-title":"MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I\/II study","volume":"21","author":"Albarran","year":"2007","journal-title":"BioDrugs"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib60","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1089\/hum.2014.024","article-title":"Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine","volume":"25","author":"Rosales","year":"2014","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2010.09.020","article-title":"Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy","volume":"204","author":"Brun","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib62","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0962-8924(02)00006-5","article-title":"Invasion of mammalian cells by Listeria monocytogenes: functional mimicry to subvert cellular functions","volume":"13","author":"Cossart","year":"2003","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib63","first-page":"10","article-title":"Live attenuated bacteria as vectors to deliver plasmid DNA vaccines","volume":"5","author":"Dietrich","year":"2003","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib64","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","article-title":"Innate immune recognition","volume":"20","author":"Janeway","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib65","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0065-2776(08)60405-8","article-title":"Confrontation between intracellular bacteria and the immune system","volume":"71","author":"Schaible","year":"1999","journal-title":"Adv Immunol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib66","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1515\/BC.2001.066","article-title":"Intracellular bacteria as targets and carriers for vaccination","volume":"382","author":"Mollenkopf","year":"2001","journal-title":"Biol Chem"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib67","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ni1088","article-title":"The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules","volume":"5","author":"Watts","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib68","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1016\/j.vaccine.2009.04.041","article-title":"The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix","volume":"27","author":"Maciag","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib69","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-065X.2008.00622.x","article-title":"Antigen-specific immunotherapy of cervical and ovarian cancer","volume":"222","author":"Hung","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib70","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.addr.2005.11.003","article-title":"Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy","volume":"58","author":"van der Burg","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib71","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.4049\/jimmunol.156.10.3911","article-title":"Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors","volume":"156","author":"Toes","year":"1996","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib72","doi-asserted-by":"crossref","first-page":"7855","DOI":"10.1073\/pnas.93.15.7855","article-title":"Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction","volume":"93","author":"Toes","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib73","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nri1149","article-title":"Mhc-guided processing: binding of large antigen fragments","volume":"3","author":"Sercarz","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib74","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/eji.200737995","article-title":"Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation","volume":"38","author":"Bijker","year":"2008","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib75","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib76","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1158\/1078-0432.CCR-15-2594","article-title":"Vaccination against oncoproteins of hpv16 for noninvasive vulvar\/vaginal lesions: lesion clearance is related to the strength of the T-cell response","volume":"22","author":"van Poelgeest","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib77","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ygyno.2005.02.012","article-title":"Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients","volume":"97","author":"van Seters","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib78","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1078\/1438-4221-00291","article-title":"The adenylate cyclase toxin from Bordetella pertussis \u2013 a novel promising vehicle for antigen delivery to dendritic cells","volume":"293","author":"Simsova","year":"2004","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib79","unstructured":"Genticel reports final results of GTL001 phase 2 trial in HPV16\/18-infected women brussels stock exchange: GTCL [Internet]. [cited 2017 Sep 6]."},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib80","first-page":"123","article-title":"Preclinical proof of concept of GTL002, a multivalent candidate for the immunotherapy of human papilloma virus HPV16\/18\/45\/31\/33\/52-infected women","author":"Esquerr\u00e9","year":"2016","journal-title":"EUROGIN"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib81","doi-asserted-by":"crossref","first-page":"12087","DOI":"10.1073\/pnas.0704672104","article-title":"Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens","volume":"104","author":"van der Burg","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib82","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.humimm.2008.02.005","article-title":"Tumor-specific regulatory T cells in cancer patients","volume":"69","author":"Piersma","year":"2008","journal-title":"Hum Immunol"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib83","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1158\/1078-0432.CCR-07-4554","article-title":"Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+\/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?","volume":"14","author":"Jordanova","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib84","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.vaccine.2008.11.042","article-title":"Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells","volume":"27","author":"Chuang","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib85","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib86","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib87","doi-asserted-by":"crossref","first-page":"262","DOI":"10.21037\/atm.2016.06.17","article-title":"Neoantigen-based cancer immunotherapy","volume":"4","author":"Bobisse","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.bpobgyn.2017.09.008_bib88","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693417301414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693417301414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T11:33:05Z","timestamp":1693049585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693417301414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":88,"alternative-id":["S1521693417301414"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2017.09.008","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic HPV vaccines","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2017.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}